Epstein Secrets

ons taken at committee meetings. The Supervisory Board therefore always had extensive and well-founded information on all matters of significance in the Evonik Group. At its meeting in March, the Supervisory Board focused on examining the annual financial state- ments, which had first been considered in detail by

2015 EVONIK INDUSTRIES At its meeting in December, the Supervisory Board discussed the Declaration of Conformity in compliance with Section 161 of the German Stock Corporation Act (AktG), the budget for 2016, the mid-term planning for the period to 2018, and progress in implementing the measures adopted following the efficien

ting, for example, from legal disputes such as claims for compensation, and from administrative proceedings and fines. In its operating busi- ness, the Evonik Group is exposed to liability risks, especially in connection with product liability, patent law, tax law, com- petition law, antitrust law and environmen

Section 315 Paragraph 4 of the German Com- mercial Code (HGB) and explanatory report by the Executive Board pursuant to Section 176 Paragraph 1 of the German Stock Corporation Act (AktG) Structure of issued capital The capital stock of Evonik Industries AG is €466,000,000 and is divided into 466,000,000 no-par registered sha

PPLEMENTARY INFORMATION Independent Auditor's Report Report on the Group Management Report We have audited the accompanying management report for the Evonik Group, which is combined with the management report of the company, Evonik Industries AG, Essen, for the business year from January 1 to December 31, 201

boards. b) Membership of comparable German and foreign supervisory bodies of business enterprises pursuant to Section 125 Paragraph 1 Sentence 5 of the German Stock Corporation Act (AMC). EFTA00598848 216 FINANCIAL REPORT 2015 EVONIK INDUSTRIES Executive Board of Evonik Industries AG Dr. Klaus Engel, Mulheirn an der Ruhr